Cellvation is a clinical-stage biopharmaceutical company developing novel cellular therapeutics for the treatment of traumatic brain injury ("TBI”). According to the Centers for Disease Control, TBI is a leading cause of death and disability in adults and children in the United States, contributing to almost one third of all injury-related mortalities. Based on the National Hospital Discharge Survey, there were approximately 2.5 million TBIs in the United States in 2010. Cellvation is currently advancing clinical-stage cell therapies for the treatment of severe TBI including: a Phase 2 study of CEVA101 in pediatric patients (ClinicalTrials.gov Identifier: NCT01851083), and a Phase 2 study of CEVA101 in adults (ClinicalTrials.gov Identifier: NCT02525432). The Phase 2 studies are supported by secured grants of approximately $10 million from the National Institutes of Health and the Department of Defense. The mechanisms of action of CEVA101 appears to be related to down-regulation of the innate neuro-inflammatory response to injury. Cellvation is also developing CEVA-D, a novel bioreactor that enhances the anti-inflammatory potency of bone marrow-derived cells without genetic manipulation. Development of the Cellvation pipeline of cellular therapeutics presents a unique opportunity to fundamentally change the approach to TBI treatment. There is no approved reparative therapy for the treatment of severe TBI. The Cellvation programs can be effective in minimizing the secondary injury associated with such injuries. Cellvation is a majority owned subsidiary of Fortress Biotech and is based in New York City.
For more information, please visit www.cellvation.com.